Title
Protective Effects of 17β-Estradiol on Benzo(e) pyrene[B(e)P]-induced Toxicity in ARPE-19 cells.

Permalink
https://escholarship.org/uc/item/36x138pc

Journal
Journal of ophthalmic & vision research, 13(4)

ISSN
2008-2010

Authors
Sapkal, Ashish U
Nashine, Sonali
Mansoor, Saffar
et al.

Publication Date
2018-10-01

DOI
10.4103/jovr.jovr_16_18

Peer reviewed
Protective Effects of 17β-Estradiol on Benzo(e)pyrene[B(e)P]-induced Toxicity in ARPE-19 cells

Ashish U. Sapkal1, MD; Sonali Nashine1, PhD; Saffar Mansoor1, PhD; Vishal R. Sharma1, MD; Claudio A. Ramirez1, MD; Rafael Z. Migon1, MD; Navin K. Gupta1, MD; Marilyn Chwa1, MS; Baruch D. Kuppermann1, MD, PhD; M. Cristina Kenney1,2, MD, PhD

1Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, CA, USA
2Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA

*Authors contributed equally to this manuscript.

Abstract

Purpose: The aim of this study was to examine the effect of 17β‑estradiol on Benzo(e)pyrene [B(e)P]‑induced toxicity in ARPE‑19 cells.

Methods: We pretreated ARPE‑19 cells with 20 nM and 40 nM 17β‑estradiol for 6 hours, followed by addition of 300 µM B(e)P for additional 24 hours. Cell viability was measured using Trypan blue dye‑exclusion assay. JC‑1 assay was performed to measure mitochondrial membrane potential (ΔΨm). For a quantitative estimation of cell death, apoptotic markers such as caspase‑3/7, caspase‑9, and caspase‑12 were measured.

Results: Our results demonstrated that when treated with B(e)P, the viability and ΔΨm of ARPE‑19 cells declined by 25% and 63%, respectively (P < 0.05). However, pretreating with 17β‑estradiol increased the viability of ARPE‑19 cells by 21% (20 nM) and 10% (40 nM) (P < 0.05). Furthermore, the significantly reduced ΔΨm in B(e)P treated cells ARPE‑19 cells was restored by pre‑treatment with 17β‑estradiol: ΔΨm was increased by 177% (20 nM) and 158% (40 nM) (P < 0.05). We further observed a significant up‑regulation in the activity of Caspases‑3/7, ‑9, and ‑12 in B(e)P‑treated ARPE‑19 cells. However, 17β‑estradiol treatment significantly reduced the activity of all apoptotic markers (P < 0.05).

Conclusion: In conclusion, our results demonstrate that 17β‑estradiol protects ARPE‑19 cells against B(e)P‑induced toxicity by decreasing apoptosis, preventing cell death, and restoring mitochondrial membrane potential.

Keywords: 17β‑Estradiol; Benzo(e)pyrene; Age‑Related Macular Degeneration; Apoptosis; Retinal Pigment Epithelial Cells; Smoking

INTRODUCTION

Cigarette smoking is a primary risk factor for age‑related macular degeneration (AMD), which is a major cause of vision loss in the United States.[1] According to the...
Age-Related Eye Disease Study (AREDS), smoking is associated with both the dry and wet forms of AMD. Current smoking has been associated with an increased incidence of geographic atrophy and choroidal neovascularization. Furthermore, current smokers are at a higher risk of developing early AMD than both past smokers and nonsmokers. A causal relation has been reported between smoking and AMD, and it has been shown that discontinuation of smoking reduces the risk for dry AMD.

Cigarette smoke contains several toxic compounds including polycyclic aromatic hydrocarbons, which have been associated with the toxic effects of cigarette smoking in several diseases, including cardiovascular and respiratory diseases. Benzo(e)pyrene [B(e)P] is a carcinogenic polycyclic aromatic hydrocarbon found in cigarette smoke. A recent study reported that B(e)P induces apoptotic cell death via caspases and Bcl-family proteins in human retinal pigment epithelial cell lines. Elevated levels of apoptosis, indicated by significantly increased number of TUNEL-positive cells, was found in AMD maculae compared to normal maculae. Moreover, B(e)P is an analog of B (a) P, which has been reported to have neurotoxic effects in several in vitro disease models.

Previous studies have revealed that various inhibitors such as Resveratrol, Genistein, and Memantine rescue ARPE-19 cells from apoptotic cell death. Resveratrol is a plant polyphenol that increases telomere length, improves mitochondrial function, and reduces oxidative stress and vascular inflammation. Genistein is a isoflavone phytoestrogen which is known to exert its neuroprotective effects by improving mitochondrial function, and by decreasing oxidative stress, inflammation, and apoptosis. Memantine is a clinically relevant drug used for neurological disorders. It potentiates its actions by inhibition of NMDARs (N-methyl-D-aspartate receptors) and decreasing β-amyloid production/toxicity. Furthermore, the crucial role of estrogen in protecting retinal cells against various cytotoxic compounds has been previously demonstrated. However, to the best of our knowledge, no study has reported the protective effects of estradiol against B(e)P-induced toxicity in ARPE-19 cells. 17β-estradiol, the primary estrogen in mammals, is involved in the development of the female phenotype by regulating gene transcription and protein synthesis, and modulates the release of gonadotrophins to induce ovulation. 17β-estradiol is an antioxidant hormone that is known to protect human retinal cells against cellular stress.

In this study, we examined the effects of 17β-estradiol on Benzo(e)pyrene-treated ARPE-19 cells. 17β-estradiol was found to confer significant protection against the deleterious effects of Benzo(e)pyrene in the human retinal pigment epithelial cells.

### METHODS

#### Cell Culture

The ARPE-19 cells (ATCC, Manassas, Virginia, USA) were grown in 1:1 mixture (v/v) of Dulbecco’s modified Eagle’s and Ham’s nutrient mixture F-12; (Invitrogen-Gibco, Carlsbad, California, USA), 10 mM non-essential amino acids, 0.37% sodium bicarbonate, 0.058% L-glutamine, 10% fetal bovine serum, and antibiotics (penicillin G 100 U/mL, streptomycin sulfate 0.1 mg/mL, gentamicin 10 mg/mL, amphotericin-B 2.5 mg/mL). Our ARPE-19 cells have been validated using RPE-specific markers already. Our recent paper demonstrated significantly higher gene expression of RPE-specific markers such as bestrophin1 (BEST1), cellular retinaldehyde binding protein-1 (CRALBP), and keratin-18 (KRT18) compared to that in MIO-M1 cell lines [Supplemental Figure 1].

Cells were incubated at standard conditions—37°C in 5% CO₂ and 95% relative humidity. After growing the cells to confluence, ARPE-19 cells were incubated for 24 hr in serum-free DMEM medium to make

[Figure 1. Effects of B(e)P and estradiol on cell viability in ARPE-19 cells: Trypan blue dye-exclusion cell viability assay showed that 300µM B(e)P decreased cell viability compared to untreated ARPE-19 cells (P < 0.001, n = 4). However, treatment with 20 nM and 40 nM estradiol (E 20nM and E 40nM respectively) increased the cell viability of B(e)P-treated ARPE-19 cells (P < 0.001 and P < 0.05, n = 4). B(e)P equivalent DMSO control, estradiol equivalent DMSO control, and estradiol equivalent control groups showed significantly higher cell viability compared to the B(e)P-alone treated cells (P < 0.001, n = 4). All values are presented as percent (%). All data are presented as mean ± standard error of mean.]

---

*Sapkal et al*
them relatively non-proliferating. Cell passage 12-15 was used; experiments were performed in triplicate, and repeated three times. “n” represents the number of times experiments were repeated in different batches of culture. Multiple wells are referred to as “replicates”.

**Exposure to B(e)P and 17β-Estradiol**

Ten milligram of 17β-estradiol (Catalog# E8875, Sigma Aldrich, St. Louis, MO) powder was dissolved in 1mL of dimethyl sulfoxide (DMSO). Then, 100 µL of this solution was diluted to 1 ml in DMSO to make a 1 mg/ml stock solution, which was further diluted in serum free culture medium. Cells were exposed to 20 nM and 40 nM 17β-estradiol for 6 hr. B(e)P powder (Catalog# B10102, Sigma Aldrich) was dissolved in DMSO to make a stock solution which was then added to the culture media to get a 300 µM working concentration. Cells were exposed to 300 µM B(e)P+βE(17β-estradiol) for 24 hr. B(e)P DMSO control and estradiol DMSO control were prepared by adding DMSO in volumes equivalent to that of B(e)P and estradiol respectively. Untreated, DMSO alone-treated, and Estradiol alone-treated cells served as controls.

**Cell Viability Assay**

Cells were plated, trypsinized, and harvested 24 hr after treatment with B(e)P. Cell viability was analyzed using the automated analyzer (Vi Cell; Beckman Coulter, Fullerton, CA). The analyzer performs an automated trypan blue dye-exclusion assay to measure the number of viable cells in the sample.

**Mitochondrial Membrane Potential (∆Ψm) Measurements**

Cells were plated at a cell density of 100,000 cells/well in 24-well plates and incubated at 37°C. Cells were exposed to B(e)P+βE for 24 hr and then incubated with the cationic JC-1 dye (5,5’6,6’-tetrachloro1,1’3,3’-tetraethyl-benzimidazolylcarbocyanine iodide) (Catalog# T3168, Life Technologies, Carlsbad, CA) at 37°C for 15 min and rinsed once with 1X PBS. The fluorescent signal was measured at 525 nm (green) and 590 nm (red) wavelengths. Ratio of red to green fluorescence was calculated and analyzed.

**Caspase Detection**

Caspase-3/7, -9, and -12 activities were detected using FLICA apoptosis detection kits (Carboxyfluorescein FLICA Apoptosis Detection kits; Immunochemistry Technologies LLC, Bloomington, MN). The FLICA reagent has an optimal excitation range 515 to 535 nm. Apoptosis was quantified as the level of fluorescence emitted by caspase bound FLICA probes. Healthy cells appeared unstained, whereas cells undergoing apoptosis fluoresced brightly. At the designated time period, the wells were rinsed briefly with fresh culture media, replaced with 300µl/well of 1x FLICA solution in culture media, and incubated at 37°C for 1 hr. Cells were then washed with PBS. The following controls were included: untreated ARPE-19 cells without FLICA were used as a background control; untreated ARPE-19 cells with FLICA for comparison of caspase activity of treated cells; buffer alone (no cells); DMSO culture media (no cells) to exclude its cross-reaction with FLICA; and ARPE-19 cells with DMSO and FLICA to account for any cross-fluorescence between untreated cells and DMSO. Quantitative calculations of caspase activities were performed using fluorescence image scanning unit (FMBIO III; Hitachi, Yokohama, Japan). Caspase activity was measured as an average signal intensity of the fluorescence.

**Statistical Analysis**

One-way ANOVA followed by the post-hoc Tukey–Kramer test was used to measure differences between 3 or more experimental groups. Differences between 2 groups were analyzed using the T-test. GraphPad Prism 5.0 software (GraphPad Software, CA, USA) was used to run all statistical tests. P values less than 0.05 were considered statistically significant.

**RESULTS**

**Cell Viability**

Cell viability was measured using the Trypan blue dye exclusion assay. Compared to untreated cells (94.55 ± 1.07%, n = 4), the cell viability in 300µM B(e) P-treated ARPE-19 cells (71.05 ± 0.72%, n = 4) decreased by 25% (P < 0.001). Compared to B(e)P-alone treated cells, cell viability was increased by 21% (P < 0.001) when pretreated with 20mM βE (86.02 ± 1.9%, n = 4) and by 10% (P < 0.05) when pretreated with 40mM βE (77.9 ± 2.2%, n = 4). Cell viability values in B(e)P equivalent DMSO control, estradiol equivalent DMSO control, and estradiol equivalent control were 96.5 ± 1.1% (n = 4), 93.9 ± 1.8% (n = 4), and 92.9 ± 1.19% (n = 4), respectively [Figure 1].

**Mitochondrial Membrane Potential (ΔΨm) Measurements**

Mitochondrial Membrane Potential (ΔΨm) was measured using JC-1 assay. Compared to untreated cells (5.94 ± 0.57 arbitrary units (a.u.)), ΔΨm of 300 µM B(e)P treated cells (2.18 ± 0.17 a.u., n = 3) was reduced by 63% (P < 0.001). Compared to B(e)P-alone treated cells, ΔΨm was significantly higher when cells were pretreated with 20 nM βE + B(e)P (177%, 6.04 ± 0.07 a.u.; P < 0.001, n = 6) and 40nM βE + B(e)P (158%, 5.63 ± 0.38 a.u.; P < 0.001, n = 6). B(e)P equivalent
DMSO control had $\Delta \Psi_m$ of $6.06 \pm 0.40$ a.u. ($n = 6$), estradiol equivalent DMSO control had $\Delta \Psi_m$ of $4.4 \pm 0.45$ a.u. ($n = 4$), estradiol equivalent control had $\Delta \Psi_m$ of $3.4 \pm 0.36$ a.u. ($n = 4$), and untreated control cultures had $\Delta \Psi_m$ of $5.94 \pm 0.58$ a.u. ($n = 6$) [Figure 2].

**Caspase-3/7 Activity**

Compared to untreated cells ($1512.6 \pm 120.7$ a.u., $n = 3$), treatment with $300 \mu M$ B(e)P ($17258.96 \pm 552.5$ a.u., $n = 3$) significantly increased the activity of caspase-3/7 by 1041% ($P < 0.001$). However, caspase-3/7 levels decreased when exposed to $20 \mu M$ $\beta E + B(e)P$ (63%, $6385.6 \pm 132.3$ a.u.; $n = 3$) ($P < 0.001$) and $40 \mu M$ $\beta E + B(e)P$ (30%, $12060.8 \pm 611.2$ a.u.; $n = 3$) ($P < 0.01$) compared to B(e)P alone. Caspase 3/7 levels in B(e)P equivalent DMSO control, estradiol equivalent DMSO control, and estradiol equivalent control were $2817.2 \pm 395.8$ a.u. ($n = 3$), $3424 \pm 598.6$ a.u. ($n = 3$), and $3496.4 \pm 473.2$ a.u. ($n = 3$), respectively [Figure 3].

**Caspase-9 Activity**

Compared to untreated cells ($2372.7 \pm 435.17$ a.u., $n = 4$), treatment with $300 \mu M$ B(e)P ($26556.04 \pm 601.48$ a.u., $n = 3$) significantly increased the activity of caspase-9 by 1019% ($P < 0.001$). Compared to B(e)P-alone treated cells, caspase-9 levels decreased when cells were exposed to $\beta E$ i.e. $20nM \beta E + B(e)P$ (23%, $20409.7 \pm 2820.9$ a.u., $P = 0.05$, $n = 4$) and $40nM \beta E + B(e)P$ (30%, $18609.7 \pm 915.6$ a.u., $P < 0.01$, $n = 4$). Caspase-9 levels in B(e)P equivalent DMSO control, estradiol equivalent DMSO control, and estradiol equivalent control were $2094.6 \pm 812.7$ a.u. ($n = 4$), $1152.5 \pm 536.7$ a.u. ($n = 4$), and $2590 \pm 240.7$ a.u. ($n = 3$), respectively [Figure 4].

**Caspase-12 Activity**

Treatment with $300 \mu M$ B(e)P caused a significant increase in caspase-12 activity ($20815.6 \pm 880.09$ a.u., $P < 0.001$, $n = 3$) compared to untreated cells ($88.8 \pm 526.7$ a.u.). Caspase‑12 levels were reduced when exposed to estradiol: $20nM \beta E + B(e)P$ (16%, $17476.8 \pm 409.4$ a.u., $n = 3$) ($P < 0.05$), and $40nM \beta E + B(e)P$ (27%, $15141.4 \pm 234.3$ a.u., $n = 3$) ($P < 0.01$). Caspase‑12 levels in B(e)P equivalent DMSO control, estradiol equivalent DMSO control, and estradiol equivalent control had $\Delta \Psi_m$ of $6.06 \pm 0.40$ a.u. ($n = 6$), estradiol equivalent DMSO control had $\Delta \Psi_m$ of $4.4 \pm 0.45$ a.u. ($n = 4$), estradiol equivalent control had $\Delta \Psi_m$ of $3.4 \pm 0.36$ a.u. ($n = 4$), and untreated control cultures had $\Delta \Psi_m$ of $5.94 \pm 0.58$ a.u. ($n = 6$) [Figure 2].

Figure 2. Effects of B(e)P and estradiol on mitochondrial membrane potential in ARPE-19 cells: JC-1 assay results demonstrated that compared to untreated ARPE-19 cells, the mitochondrial membrane potential ($\Delta \Psi_m$) was reduced with $300 \mu M$ B(e)P alone-treated cells ($P < 0.001$, $n = 6$). Addition of $20nM$ and $40nM$ estradiol significantly increased the $\Delta \Psi_m$ in B(e)P ARPE-19 cells ($P < 0.05$, $n = 6$). Compared to B(e)P alone-treated cells, elevated mitochondrial membrane potential was found in B(e)P equivalent DMSO control, estradiol equivalent DMSO control, and estradiol equivalent control groups ($P < 0.05$, $n = 6$). All values are presented in arbitrary units (a.u.). All data are presented as mean ± standard error of mean.

Figure 3. Effects of B(e)P and estradiol on caspase-3/7 activity in ARPE-19 cells: The FLICA caspase-3/7 assay results demonstrated significantly elevated caspase-3/7 activity in B(e)P-alone treated ARPE-19 cells ($P < 0.001$, $n = 3$) compared to untreated cells. Pretreatment with $20nM$ and $40nM$ estradiol led to drastic decrease in caspase-3/7 activity in B(e)P-treated cells ($P < 0.001$, $n = 3$). In addition, caspase-3/7 activity was reduced significantly in estradiol equivalent control, estradiol equivalent DMSO control, and in B(e)P equivalent DMSO control groups ($P < 0.001$, $n = 3$). All values are presented in arbitrary units (a.u.). All data are presented as mean ± standard error of mean.
equivalent control were 1676.5 ± 471.8 a.u. (n = 3), 1656.9 ± 627.9 a.u. (n = 3), and 1189.9 ± 266.9 a.u. (n = 3), respectively [Figure 5].

DISCUSSION

The present study demonstrated the protective role of 17β-estradiol in rescuing ARPE-19 cells from B(e)P-induced toxicity. Pretreatment with 17β-estradiol prevented cell loss and collapse of mitochondrial membrane potential in B(e)P-treated ARPE-19 cells. Furthermore, reduced apoptosis caused by 17β-estradiol was evident, since there was a decline in the activity of caspases-3/7, -9, and -12 in B(e)P-treated ARPE-19 cells.

Similar to the results of our study, previous studies have demonstrated that 17β-estradiol protects ARPE-19 cells against hydrogen peroxide-induced oxidative stress. 17β-estradiol is neuroprotective and prevents loss of retinal ganglion cells in a glaucoma model. It has been reported that the antioxidant activity of 17β-estradiol protects neurons from oxidative stress-induced cell death in vitro in a mouse hippocampal cell line - HT22. In that study, 17β-estradiol protected neurons by blocking glutamate-mediated DNA degradation. Moreover, administration of 17β-estradiol protects against retinal ischemia-induced tissue damage in rats. In general, the role of estrogen as a neuroprotective agent has been well-established. Recent studies have highlighted the neuroprotective effect of estrogens on retinal neurons in vitro against oxidative stress. Estrogen has been reported to protect against cataract development and uveitis.

Previous studies have shown that younger women have higher levels of estrogen compared to the aging and post-menopausal women. Furthermore, smoking is known to diminish the protective ability of estrogen. Therefore, it could be speculated that aging-related decline in estrogen levels might be increasing the susceptibility to the toxic effects of cigarette smoking. Hormone replacement therapy has been reported to lower intraocular pressure in menopausal women and improve cognitive function. Furthermore, postmenopausal hormone therapy is known to increase retinal blood flow and protects the retinal nerve fiber layer. Evidently, estrogen has been implicated to be beneficial in the treatment of various visual disorders.

B(e)P is known to cause toxicity by mediating apoptotic cell death and DNA fragmentation in ARPE-19 cells. It has been reported that 17β-estradiol,
an antioxidant, mediates its cytoprotective effects via preservation of mitochondrial function and reduction of apoptosis in ARPE-19 cells.\textsuperscript{[7]} Consistent with those findings, our study revealed that 17β-estradiol prevented cell death and preserved mitochondrial function by restoring mitochondrial membrane potential in B(e)P treated ARPE-19 cells. In addition, our results demonstrated that 17β-estradiol led to a substantial decrease in the activity of caspases in B(e)P treated ARPE-19 cells. Caspases are normally present in cells as inactive proenzymes, and activation of caspases is a biochemical hallmark of apoptosis.\textsuperscript{[34]} In order to quantitate the additive effects of 17β-estradiol and B(e)P on apoptotic activity, we used the FLICA probes which are cell permeant, non-cytotoxic fluorescent labeled inhibitors of caspases. These probes covalently and irreversibly bind to active caspase enzymes. Apoptotic cells which retain a higher concentration of FLICA, exhibit brighter green fluorescence compared to healthy cells. In our study, treatment with 17β-estradiol led to a drastic decline in the activity caspase-9, an initiator caspase, in B(e)P treated ARPE-19 cells. Cellular stress causes release of mitochondrial cytochrome c into the cytosol. Cytochrome c binds APAF-1, an adaptor protein, which in turn recruits caspase-9 to form a multiprotein complex called the apoptosome. Once activated, caspase-9 is cleaved and activates executioner/effector caspases, which eventually leads to the degradation of cellular components.\textsuperscript{[35]} The current study also demonstrated that in B(e)P treated ARPE-19 cells, 17β-estradiol lowered the activity of caspase-3/7, and caspase-12. Caspase-3 and caspase-7 are effector caspases that are closely related to each other and are universally activated in response to cell death stimuli in various cell types including retinal cells. Caspase-3 is activated in the apoptotic cell both by extrinsic (via death ligand), and intrinsic (mitochondrial) pathways, and is known to mediate feedback processing of caspase-9.\textsuperscript{[36]} Caspase-12 is known to be activated by ER stress and has been linked to inflammatory responses.\textsuperscript{[37,38]} Our results are consistent with previous studies by Lee et al and Pelzer et al that reported that 17β-estradiol caused a decline in apoptosis via reduction of caspase activity in hepatocytes and cardiac myocytes respectively.\textsuperscript{[39,40]}

To summarize, this study presents important findings that emphasize the prominent role of 17β-estradiol in protecting human retinal pigment epithelial cells against the toxic effects of Benzo(e)pyrene. These results suggest that administration of 17β-estradiol may be considered to prevent retinal cell damage caused by cigarette smoke. Further studies are required to examine the mechanisms by which 17β-estradiol mediates its protective effects against B[e]P-induced cellular toxicity in ARPE-19 cells.

Acknowledgement
Supported by the Discovery Eye Foundation, Polly and Michael Smith, Iris and B. Gerald Cantor Foundation, Henry L. Guenther Foundation, Lincy Foundation, and an unrestricted grant from Research to Prevent Blindness.

Financial Support and Sponsorship
Supported by the Discovery Eye Foundation, Polly and Michael Smith, Iris and B. Gerald Cantor Foundation, Henry L. Guenther Foundation, Lincy Foundation, and an unrestricted grant from Research to Prevent Blindness.

Conflicts of Interest
There are no conflicts of interest.

REFERENCES
1. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP, et al. Smoking and age-related macular degeneration: A review of association. Eye (Lond) 2005;19:935-944.
2. Klein R, Knudtson MD, Cruickshanks KJ, Klein BE. Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration: The beaver dam eye study. Arch Ophthalmol 2008;126:115-121.
3. Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, et al. Smoking and age related macular degeneration: The number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006;90:75-80.
4. Talhout R, Schulz T, Florek E, van Benthem J, Wester P, Opperhuizen A, et al. Hazardous compounds in tobacco smoke. Int J Environ Res Public Health 2011;8:613-628.
5. Ambrose JA, Barua KS. The pathophysiology of cigarette smoking and cardiovascular disease: An update. J Am Coll Cardiol 2004;43:1731-1737.
6. Rubin H. Synergistic mechanisms in carcinogenesis by polycyclic aromatic hydrocarbons and by tobacco smoke: A bio-historical perspective with updates. Carcinogenesis 2001;22:1903-1930.
7. Sharma A, Neekhra A, Gramajo AL, Patil J, Chwa M, Kuppermann BD, et al. Effects of Benzo(e)Pyrene, a toxic component of cigarette smoke, on human retinal pigment epithelial cells in vitro. Invest Ophthalmol Vis Sci 2008;49:5111-5117.
8. Mansoor S, Gupta N, Patil AJ, Estrago-Franco MF, Ramirez C, Migon R, et al. Inhibition of apoptosis in human retinal pigment epithelial cells treated with Benzo(e)Pyrene, a toxic component of cigarette smoke. Invest Ophthalmol Vis Sci 2010;51:2601-2607.
9. Patil AJ, Gramajo AL, Sharma A, Chwa M, Seigel GM, Kuppermann BD, et al. Effects of benzo(e)pyrene on the retinal neurons from human and microvascular endothelial cells in vitro. Curr Eye Res 2009;34:672-682.
10. Dunaief JL, Dencchev T, Ying GS, Milam AH. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol 2002;120:1435-1442.
11. Cheng SQ, Xia YY, He JL, Liu XQ, Chen XM, Ding YB, et al. Neurotoxic effect of subacute benzo (a) pyrene exposure on gene and protein expression in Sprague-Dawley rats. Environ Toxicol Pharmacol 2013;36:648-658.
12. Das SK, Patel B, Patri M. Neurotoxic effect of Benzo[a] Pyrene
and its possible association with 6-hydroxydopamine induced neurobehavioral changes during early adolescence period in rats. J Toxicol 2016;2016:806410.

13. Saunders CR, Das SK, Ramesh A, Shockley DC, Mukherjee S. Benzo(a)pyrene-induced acute neurotoxicity in the F-344 rat: Role of oxidative stress. J Appl Toxicol 2006;26:427-438.

14. Dong W, Zhou Y, Yang Z. Research progress of mechanism of action of resveratrol. Pharmacol Pharm 2016;7:170-175.

15. Schreihofer DA, Oppong-Gyebi A. Genistein: Mechanisms of action for a pleiotropic neuroprotective agent in stroke. Nutr Neurosci 2017;1-17. [Epub ahead of print].

16. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2016;6:61-67.

17. Kaja S, Yang SH, Wei J, Fujitani K, Liu R, Brun-Zinkernagel AM, et al. Estrogen protects the inner retina from apoptosis and ischemia-induced loss of vesl-1L/Homer 1c Immunoreactive synaptic connections. Invest Ophthalmol Vis Sci 2003;44:3155-3162.

18. Na KS, Jee DH, Han K, Park YG, Kim MS, Kim EC, et al. The ocular benefits of estrogen replacement therapy: A population-based study in postmenopausal Korean women. PLoS One 2014;9:e106473.

19. Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: Pharmacokinetics, pharmacodynamics and risk assessment. Contraception 2013;87:706-727.

20. Li C, Tang Y, Li F, Turner S, Li K, Zhou X, et al. 17beta-estradiol (betaE2) protects human retinal Müller cell against oxidative stress in vitro: Evaluation of its effects on gene expression by cDNA microarray. Glia 2006;53:392-400.

21. Moustafa MT, Ramirez C, Schneider K, Atilano SR, Limb GA, Kuppermann BD, et al. Protective effects of memantine on hydroquinone-treated human retinal pigment epithelial cells and human retinal Müller cells. J Ocul Pharmacol Ther 2017;33:610-619.

22. Giddabasappa A, Bauler M, Yepuru M, Chaum E, Dalton JT, Eswaraka J, et al. 17-β estradiol protects ARPE-19 cells from oxidative stress through estrogen receptor-β. Invest Ophthalmol Vis Sci 2010;51:5278-5287.

23. Prokai-Tatrai K, Xin H, Nguyen V, Szarka S, Blazics B, Prokai I, et al. 17β-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vitro model of glaucoma. Mol Pharm 2013;10:3253-3261.

24. Behl C, Widmann M, Trapp T, Holsboer F. 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun 1995;216:473-482.

25. Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Miyamoto K, Nishiwaki H, et al. Administration of 17beta-estradiol attenuates retinal ischemia-reperfusion injury in rats. Invest Ophthalmol Vis Sci 2000;41:2689-2696.

26. Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM. Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications. Steroids 2007;72:381-405.

27. Cao W, Rajala RV, Li F, Anderson RE, Wei N, Soliman CE, et al. Neuroprotective effect of estrogen upon retinal neurons in vitro. Adv Exp Med Biol 2003;533:395-402.

28. Hales AM, Chamberlain CG, Murphy CR, McAvoy JW. Estrogen protects lenses against catacaract induced by transforming growth factor-beta (TGFbeta). J Exp Med 1997;185:273-280.

29. Miyamoto N, Mandai M, Suzuma I, Suzuma K, Kobayashi K, Honda Y, et al. Estrogen protects against cellular infiltration by reducing the expressions of E-selectin and IL-6 in endotoxin-induced uveitis. J Immunol 1999;163:374-379.

30. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 1998;279:688-695.

31. Mueck AO, Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Curr Med Chem Cardiovasc Hematol Agents 2005;3:45-54.

32. Sato MO, Joura EA, Frigo P, Kurcz C, Metka M, Hommer A, et al. Hormone replacement therapy and intraocular pressure. Maturitas 1997;28:55-58.

33. Deschênes MC, Descovich D, Moreau M, Granger L, Kuchel GA, Mikkola TS, et al. Postmenopausal hormone therapy increases retinal blood flow and protects the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 2010;51:2587-2600.

34. Saraste A, Pulikki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 2000;45:528-537.

35. Creagh EM. Caspase crossstalk: Integration of apoptotic and innate immune signalling pathways. Trends Immunol 2014;35:631-640.

36. Walsh JG, Cullen SP, Sheridan C, Lüthi AU, Gerner C, Martin SJ, et al. Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci U S A 2008;105:12815-12819.

37. Nakagawa T, Yuan J. Cross-talk between two cytostane protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol 2000;150:887-894.

38. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000;403:98-103.

39. Lee MY, Jung SC, Lee JH, Han HJ. Estriol-17beta protects against hypoxia-induced hepatocyte injury through ER-mediated upregulation of Bcl-2 as well as ER-independent antioxidiant effects. Cell Res 2008;18:491-499.

40. Pelzer T, Schumann M, Neumann M, deJager T, Stimpel M, Serfling E, et al. 17beta-estradiol prevents programmed cell death in cardiac myocytes. Biochem Biophys Res Commun 2000;268:192-200.
Supplemental Figure 1. ARPE-19 CellMarkers.

| Gene Symbol | Gene ID | RefSeq ID | Exon Coverage | ARPE Marker | MIO Marker |
|-------------|---------|-----------|---------------|-------------|-------------|
| RLBP1 (CRALBP) | 6017 | NM_000326 | 2-3 | ARPE Marker |             |
| KRT18 | 3875 | NM_000224 | 3-4 | ARPE Marker |             |
| ACTA2 | 59 | NM_001141945 | 8-9 | MIO Marker |             |
| GFAP | 2670 | NM_002055 | 6-8 | MIO Marker |             |

All values normalized to ARPE19

|        | RLBP1 (ARPE Marker) | KRT18 (ARPE Marker) | ACTA2 (MIO Marker) | GFAP (MIO Marker) |
|--------|---------------------|---------------------|-------------------|-------------------|
| ARPE19 | 1                   | 1                   | 1                 | 1                 |
| MIO    | 0.1583              | 0.016136            | 3.44              | 21.6              |

ARPE 6.39 fold higher
ARPE 62.0 fold higher
MIO 3.44 fold higher
MIO 21.6 fold higher

CRALBP Higher expression in ARPE (Matches Expected Results)
KRT18 Higher expression in ARPE (Matches Expected Results)
ACTA2 Higher expression in MIO (Matches Expected Results)
GFAP Higher in MIO (Matches Expected Results)